Search

Your search keyword '"Vannucchi, Alessandro"' showing total 3,354 results

Search Constraints

Start Over You searched for: Author "Vannucchi, Alessandro" Remove constraint Author: "Vannucchi, Alessandro"
3,354 results on '"Vannucchi, Alessandro"'

Search Results

1. Chromosome 9p trisomy increases stem cells clonogenic potential and fosters T-cell exhaustion in JAK2-mutant myeloproliferative neoplasms

6. Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes

8. Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial

9. Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis

15. Inhibition of ERK1/2 signaling prevents bone marrow fibrosis by reducing osteopontin plasma levels in a myelofibrosis mouse model

16. Functional relevance of circRNA aberrant expression in pediatric acute leukemia with KMT2A::AFF1 fusion

17. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

18. Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group

19. Biological drivers of clinical phenotype in myelofibrosis

21. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study

23. Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials

24. Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients

26. Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT

28. Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia

29. Safety and efficacy of fedratinib in patients with myelofibrosis previously treated with ruxolitinib: primary analysis of FREEDOM trial

30. Updated safety and efficacy data from the phase 3 MANIFEST-2 study of pelabresib in combination with ruxolitinib for JAK inhibitor treatment-naïve patients with myelofibrosis.

35. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

36. Mepolizumab Reduces Hypereosinophilic Syndrome Flares Irrespective of Blood Eosinophil Count and Interleukin-5

38. A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia

39. Second versus first wave of COVID-19 in patients with MPN

40. Breakthrough infections in MPN-COVID vaccinated patients

41. Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score

42. Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations

43. The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study

44. Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial

45. Disease correlates and clinical relevance of hereditary α-tryptasemia in patients with systemic mastocytosis

48. Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study

50. Safety and Efficacy of Mepolizumab in Hypereosinophilic Syndrome: An Open-Label Extension Study

Catalog

Books, media, physical & digital resources